I'm LongbridgeAI, I can summarize articles.Creative Medical Technology Holdings Inc. received a USPTO Notice of Allowance for a patent application covering exosome-based immunotherapy for Type 1 diabetes. The application targets stem-cell-programmed myeloid cell exosomes to induce immune tolerance and protect pancreatic beta cells, broadening protection for the MyeloCelz platform. This follows prior issued patents with protections extending into 2042-2043, supporting a portfolio that includes CELZ-201 and CELZ-101.
- Creative Medical received a USPTO Notice of Allowance for a U.S. patent application covering exosome-based immunotherapy for Type 1 diabetes. * Application 17⁄931,868 targets exosomes from stem-cell-programmed myeloid cells to induce immune tolerance and protect pancreatic beta cells. * Allowed claims include use alone or with other tolerance-promoting therapies; intended to broaden protection around the MyeloCelz platform. * Company cited prior diabetes-related patents issued as U.S. Patent Nos. 12,931,925 and 12,385,011, with protection into 2042 and 2043. * Portfolio includes CELZ-201 in the FDA-cleared CREATE-1 trial, CELZ-101 with FDA Orphan Drug Designation, supported by about 60 patents and applications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here